CB1 receptor and psychosis: friend, foe, or both
Jagadeesh Sridhara Rao, María Alejandra Tangarife, Diego A. Rodríguez‐Soacha, Ram Mukunda
Frontiers in Psychiatry July 22, 2025 DOI: 10.3389/fpsyt.2025.1630080 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Key points | Contends that schizophrenia and Alzheimer's disease, despite differing onset of psychosis, share limbic system involvement with predominant medial temporal atrophy and common dopaminergic and cholinergic disturbances, and that psychosis affects approximately 40 to 60% of people with Alzheimer's disease. |
Abstract
Psychosis is a core issue in Schizophrenia (SZ), whereas in Alzheimer's disease (AD), the prevalence of psychosis, particularly hallucinations and delusions, is approximately 40 to 60% (1). The onset of psychosis varies in SZ and AD but shares similar structural, neurochemical changes, and genetic associations (2). Radiological and pathological studies reveal a common pattern of limbic system involvement in both SZ and AD, with predominant atrophy in the medial temporal regions. Both conditions also share core neurochemical disturbances, particularly affecting the dopaminergic and cholinergic systems (3).
Citations in the library
Cites 5
- DNA methylation at cannabinoid type 1 and dopamine D2 receptor genes in saliva samples of psychotic subjects: Is there an effect of Cannabis use? Pharmacological Research October 2024
- Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment. Pharmacological Research December 1, 2021
- Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal Δ9-tetrahydrocannabinol-exposed rats. Pharmacological Research February 2021
- Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia. Journal of Clinical Psychopharmacology June 2009
- Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophrenia Research August 2007